|

A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors

NOT_RECRUITINGPhase 2Sponsored by CellSight Technologies, Inc.
No longer actively recruiting
PhasePhase 2
SponsorCellSight Technologies, Inc.
Started2022-03-01
Est. completion2026-11-30
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations2 sites
View on ClinicalTrials.gov →

NCT04260256

Summary

In this study, patients with advanced solid tumors will undergo \[18F\]F AraG PET/CT imaging to assess for changes in tracer uptake following treatment with CkIT.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Solid tumor with planned CkIT
* Must be \>18 years old
* Signed Informed Consent Form
* Patient must have two qualifying lesions

Exclusion Criteria:

* Patient is pregnant or breast feeding

Conditions2

CancerCorrelate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit

Interventions1

[18F]F-AraG

Locations2 sites

California

1 site
Stanford University
Stanford, California, 94305
Kavin Tamizhmani650-497-6046ktamizhm@stanford.edu

Oregon

1 site
Oregon Health and Science University
Portland, Oregon, 97239
Libby Mirande503-494-4740jenselib@ohsu.edu

Find trials near these locations

All trials in CaliforniaAll trials in Oregon

Related trials

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.